Peter Dritschilo
President chez SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Fortune : 2 617 $ au 30/04/2024
Profil
Peter Dritschilo currently works at Shuttle Pharmaceuticals, Inc., as President & Chief Operating Officer from 2012 and Shuttle Pharmaceuticals Holdings, Inc., as President & Chief Operating Officer.
Mr. Dritschilo received his undergraduate degree from Georgetown University and Masters Business Admin degree from The GW School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/03/2024 | 6 560 ( 0,04% ) | 2 617 $ | 30/04/2024 |
Postes actifs de Peter Dritschilo
| Sociétés | Poste | Début |
|---|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | President | 18/12/2012 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | President | 01/12/2012 |
Formation de Peter Dritschilo
| Georgetown University | Undergraduate Degree |
| The GW School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
